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Recommendations for Blood Lead Screening of Medicaid-Eligible 
Children Aged 1–5 Years: an Updated Approach to Targeting a 
Group at High Risk
Anne M. Wengrovitz, MPH, Mary Jean Brown, ScD
Advisory Committee on Childhood Lead Poisoning, Division of Environmental and Emergency Health Services, National Center for Environmental Health
Summary
Lead is a potent, pervasive neurotoxicant, and elevated blood lead levels (EBLLs) can result in decreased IQ, academic failure, 
and behavioral problems in children. Eliminating EBLLs among children is one of the 2010 U.S. national health objectives. Data 
from the National Health and Nutrition Examination Survey (NHANES) indicate substantial decreases both in the percentage of 
persons in the United States with EBLLs and in mean BLLs among all age and ethnic groups, including children aged 1–5 years. 
Historically, children in low-income families served by public assistance programs have been considered to be at greater risk for 
EBLLs than other children. However, evidence indicates that children in low-income families are experiencing decreases in BLLs, 
suggesting that the EBLL disparity between Medicaid-eligible children and non–Medicaid-eligible children is diminishing. In 
response to these findings, the CDC Advisory Committee on Childhood Lead Poisoning Prevention is updating recommendations 
for blood lead screening among children eligible for Medicaid by providing recommendations for improving BLL screening and 
information for health-care providers, state officials, and others interested in lead-related services for Medicaid-eligible children. 
Because state and local officials are more familiar than federal agencies with local risk for EBLLs, CDC recommends that these 
officials have the flexibility to develop blood lead screening strategies that reflect local risk for EBLLs. Rather than provide universal 
screening to all Medicaid children, which was previously recommended, state and local officials should  target screening toward 
specific groups of children in their area at higher risk for EBLLs. This report presents the updated CDC recommendations and 
provides strategies to 1) improve screening rates of children at risk for EBLLs, 2) develop surveillance strategies that are not solely 
dependent on BLL testing, and 3) assist states with evaluation of screening plans. 
Introduction
Substantial improvements have been made in reducing lead 
in the environment. During 1999–2004, 1.4% of children 
in the United States aged 1–5 years had elevated blood lead 
levels (EBLLs) (1), compared with 8.6% of children during 
1988–1991. Despite this progress, some children remain at 
risk, and eliminating EBLLs among all children aged 1–6 
years is a 2010 national health objective (objective 8–11) (2). 
To meet this objective, the limited available resources must be 
focused on the populations at highest risk for EBLLs. Since 
1989, children who are eligible for Medicaid have been identi-
fied as having an increased risk for lead exposure. This finding 
forms the basis for the current national Medicaid policy, which 
targets Medicaid-eligible children for preventive and screening 
measures, including routine blood lead testing. However, evi-
dence from several states indicates that children in low-income 
families are experiencing decreases in BLLs. This underscores 
the need for closer analysis of the lead risk patterns within vari-
ous jurisdictions and suggests that children who are eligible for 
Medicaid can no longer be assumed to have an increased risk 
for EBLLs. Therefore, a new blood lead screening strategy is 
needed that accounts for local variations in risk and disparities 
at the local level. This report reviews available data on child-
hood lead exposure in the United States, especially among 
children aged 1–5 years who are eligible for Medicaid, updates 
screening recommendations for this population, and describes 
relevant Medicaid program requirements and changes. 
The national objective to eliminate EBLLs among children 
by 2010 is part of a larger national goal to eliminate health 
disparities among various segments of the population (Goal 2) 
(2). Improved blood lead screening policies and practices also 
support the “healthy people in healthy places” component of 
CDC’s core health protection goals, which aim to promote and 
protect health through safe and healthy home environments 
(3). In 2000, CDC, the Department of Housing and Urban 
Development (HUD), the Environmental Protection Agency 
(EPA), and other agencies developed a federal interagency 
strategy to eliminate EBLLs among children by 2010. An 
important element of this interagency strategy is identification 
and care of children with EBLLs, especially Medicaid-eligible 
children (4).
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Methods
The National Health and Nutrition Examination Survey 
(NHANES) is an ongoing series of cross-sectional surveys 
on health and nutrition designed to be nationally representa-
tive of the noninstitutionalized, U.S. civilian population by 
using a complex, multistage probability design. All NHANES 
surveys include a household interview followed by a detailed 
physical examination. NHANES data indicate substantial 
decreases since 1976 in both the percentage of persons in the 
United States with EBLLs and in mean BLLs among all age 
and ethnic groups.
The CDC Advisory Committee on Childhood Lead 
Poisoning Prevention (ACCLPP) makes recommendations 
to improve lead poisoning prevention measures. In 2001, in 
response to the decreased prevalence of EBLLs in the United 
States, ACCLPP formed a workgroup to 1) review the pub-
lished research regarding screening of children at high risk for 
EBLLs and 2) outline recommendations for state Medicaid 
agencies to determine whether risk for lead exposure among 
Medicaid-eligible children overall is higher than for non–
Medicaid-eligible children in their jurisdictions. The Centers 
for Medicare & Medicaid Services (CMS), which is the admin-
istrator of the Medicaid program, reviewed the recommenda-
tions developed by the workgroup. The recommendations were 
approved by ACCLPP in September 2008. 
Blood Lead Levels and Exposure 
Patterns Among Children
Lead has been associated with numerous adverse health 
effects in humans (5). In children, even BLLs <10 µg/dL can 
result in decreased cognitive function, developmental delays, 
and behavior problems (6). These adverse effects reinforce the 
importance of screening and continued measures to eliminate 
or control lead sources in children’s environments. Regulations 
that limit the use of lead in gasoline, paint, plumbing solder, 
food cans, and other consumer products and that control or 
eliminate residential lead paint hazards not only support the 
2010 goal of eliminating EBLLs but also help prevent adverse 
health effects at lower exposure levels (7,8).
national Prevalence Estimates and 
Trends
Data from NHANES indicate that during 1976–2004, a 
substantial decrease occurred in the percentage of young chil-
dren aged 1–5 years with EBLLs (77.8% during 1976–1980, 
4.4% during 1991–1994, and 1.4% during 1999–2004) (1,9). 
BLLs have decreased among all age and ethnic groups (10). 
However, NHANES data indicate that disparities continue 
to exist in mean BLL by race, income level, age of residence, 
and other available risk factors. Data from the 1991–1994 
NHANES indicated that the highest rates of EBLLs occurred 
among children living in homes built before 1946, among 
children in low-income families, and among children who 
were either non-Hispanic black or Mexican-American (9). 
The percentage of EBLLs among black children aged 1–5 years 
(11.2%) was significantly higher than among white children 
(2.3%) (p<0.05). By 1999–2004, the difference between 
black (3.4%) and white (1.2%) children in this age group had 
decreased substantially (1).* In addition, in the 1991–1994 
NHANES survey, black, non-Hispanic children had a geomet-
ric mean (GM) BLL of 4.3 µg/dL, compared with 2.3 µg/dL for 
white, non-Hispanic children.  In the 1999–2004 NHANES 
survey, the GM BLL for black, non-Hispanic children was 
2.8 µg/dL, compared with a GM BLL of 1.7 µg/dL for white, 
non-Hispanic children (1). In the 1999–2004 NHANES 
survey, children in low-income families had a GM BLL of 
2.4 µg/dL, compared with 1.5 µg/dL for children aged 1–5 
years in higher-income families (1).
State Surveillance Data and Trends
As disparities among subpopulations have decreased, accu-
rately assessing the risk for lead exposure among children has 
become more difficult, especially on a national level, because 
NHANES is not constructed to measure prevalence in small 
populations. Thus, state and local data have gradually become 
more important than national data for developing lead expo-
sure prevention policies at the state and local level.
The downward national trend in BLLs indicated by the 
NHANES survey data is substantiated by lead surveillance data 
collected by states and reported to CDC (11). Results from 
tests of children aged <72 months who were screened for lead 
at least once during January 1, 1997, through December 31, 
2004, show similar patterns in most states: decreasing num-
bers of confirmed EBLL cases and decreasing percentages of 
confirmed EBLLs among children tested (12). The nationwide 
decrease in the number of new EBLL cases in states that screen 
numerous children (both in the general and Medicaid-eligible 
populations) as well as states that screen fewer children sug-
gests that the decrease in EBLL cases is not merely a function 
of increased proportions of lower-risk children being tested or 
fewer children at high risk for EBLLs being tested. 
* Because of small proportions and variability of the estimates, the statistical sig-
nificance of the difference between these percentages could not be determined.
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Medicaid Eligibility and Risk for Lead 
Exposure 
Studies conducted during the 1980s and 1990s indicated 
that children eligible for Medicaid were at increased risk for 
lead exposure (13) and that children living in poverty had 
higher levels of lead exposure than those who were not living in 
poverty (14). Using data from the 1991–1994 NHANES, the 
U.S. General Accounting Office found that 60% of children 
with BLLs >10 µg/dL and 83% of those with BLLs >20 µg/dL 
were eligible for Medicaid (13,15). A separate CDC analysis of 
the same NHANES data estimated that approximately 93% of 
children with BLLs >20 µg/dL were Medicaid eligible (16). A 
subsequent analysis of all 1988–1994 NHANES data found 
that families who reported having Medicaid coverage were 
more likely to have EBLLs than those who were not enrolled 
in Medicaid (16). Such findings supported a focus on identify-
ing cases of EBLL among Medicaid children to provide early 
intervention and treatment and develop focused prevention 
strategies (17). Medicaid eligibility, as well as eligibility for 
other programs for low-income families, is a proxy for poverty 
and therefore for living in old, poorly maintained housing, 
which is more likely to contain lead paint hazards.
As a result of increased lead screening for Medicaid children, 
recent data are available that provide a more detailed char-
acterization of this population’s risk for EBLLs. An analysis 
of Minnesota data indicated that the percentage of tested 
children aged <72 months who had EBLLs decreased from 
7.8% to 3.5% during 1999–2003 among children enrolled 
in Medicaid and from 4.1% to 1.9% among children not 
enrolled in Medicaid. This suggests that, in Minnesota, BLLs 
are decreasing in children eligible for Medicaid as well as in the 
general population (18). A study of children enrolled in the 
Special Supplemental Nutrition Program for Women, Infants, 
and Children (WIC program) in Wisconsin (i.e., a popula-
tion of children from lower-income families) found decreas-
ing rates of EBLLs during 1996–2000 (19). A CDC analysis 
of 1999–2004 NHANES data found that the distribution 
of BLLs by poverty status, as indicated by both a household 
income <1.3 times the poverty threshold for the year of the 
interview and Medicaid enrollment, had shifted toward lower 
values, and the percentage of children with EBLLs enrolled 
in Medicaid was not statistically significantly higher than the 
percentage of children with EBLLs not enrolled in Medicaid 
(1). These studies are consistent with programmatic experi-
ence and suggest that children in low-income families served 
by Medicaid and WIC have experienced a decrease in BLLs 
similar to the decrease in the general population. In addition, 
the disparity in risk for lead exposure between Medicaid-
eligible children and non–Medicaid-eligible children might be 
decreasing. These results indicate that children who are eligible 
for Medicaid can no longer be assumed to have an increased 
risk for EBLLs. Thus, rather than a single national policy that 
is used for all Medicaid children, a new blood lead screening 
strategy is needed that accounts for local variations in risk and 
disparities at the local level.
Blood Lead Screening Policies
CDC Policies
The primary purpose of childhood blood lead screening 
has been to identify asymptomatic children with EBLLs 
so that they can promptly receive services to reduce lead 
exposure and improve health outcomes. As early as 1978, 
CDC recommended universal screening of all children aged 
9 months–6 years but emphasized screening children with 
specific risk factors, such as children living in substandard 
housing or those in low-income families (20). 
In 1997, CDC recognized that the prevalence of EBLLs 
among young children had decreased substantially and that 
the risk for lead exposure varied substantially by geographic 
location. CDC replaced its recommendation for universal 
screening of all children aged 9 months–6 years with a recom-
mendation for targeted screening to identify children most 
likely to have EBLLs and to benefit from screening. The 1997 
CDC recommendation called for states to analyze their BLL 
data and develop state screening plans consistent with state and 
local risk patterns (21). CDC also recommended continued 
universal screening of Medicaid-eligible children, assuming 
that all such children were at risk for EBLLs, “unless there [are] 
reliable, representative BLL data that demonstrate the absence 
of lead exposure in this population” (21). 
As an interim measure, until state or local data became avail-
able, CDC recommended two blood lead tests for children 
determined to be at higher risk for EBLLs, one at age 9–12 
months and one at age 2 years, because on average, BLLs peak 
at 24 months (22). In addition, CDC recommended that 
children at high risk for EBLLs who have never been tested be 
tested at age 3 years. Since 1997, officials in certain states and 
jurisdictions have developed blood lead testing requirements 
that also require testing for children at older ages. Information 
on state-specific blood lead screening plans is available at http://
www.cdc.gov/nceh/lead.
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CMS Policies: The Early and Periodic 
Screening, Diagnostic, and Treatment 
Service 
Since 1989, federal Medicaid law has included the require-
ment that states provide blood lead assessments, as indicated 
by age and risk factors, as part of the medical screening, health 
education, and anticipatory guidance regarding EBLLs and 
to provide medically necessary treatment services.† The law 
requires lead screening of young children eligible for Medicaid, 
one element of Medicaid’s Early and Periodic Screening, 
Diagnostic, and Treatment (EPSDT) service, a program that 
entitles children to comprehensive preventive health care and 
necessary diagnosis and treatment. The State Medicaid Manual 
is the principal CMS document that provides guidance to 
states on specific program requirements; agency policy inter-
pretations and clarifications are occasionally issued through a 
letter signed by a CMS official (23). Consistent with federal 
law and CDC recommendations, current CMS policy requires 
that 1) all children receive a blood lead test at ages 12 months 
and 24 months, and 2) children aged 36–72 months receive 
a blood lead test if they have not been previously tested (24). 
CMS also specifies that “states may not adopt a statewide plan 
for screening children for EBLLs that does not require lead 
screening for all Medicaid-eligible children” (23). 
Implementing a change in policy for lead screening of 
Medicaid-eligible children will involve an update of the State 
Medicaid Manual by CMS. In 2009 and 2010, CDC will 
advise CMS regarding which states have sufficient data to 
assess differences between the prevalence of EBLLs in children 
eligible for Medicaid and the general population of children 
in the state. In states where the risk for EBLLs is determined 
to be no higher for Medicaid-eligible children than for other 
children in the state, CMS will either update the State Medicaid 
Manual directly or provide a letter to the Medicaid directors 
in these states informing them that blood lead screening is no 
longer required for all Medicaid-eligible children.
Recommendations
Following are the updated CDC recommendations for 
blood lead screening of children aged 1–5 years who are 
eligible for Medicaid. CDC recommends that state and local 
public health officials 1) update blood lead screening policies 
for Medicaid-eligible children, 2) improve rates of blood lead 
screening among Medicaid-eligible children determined to be 
at increased risk for lead exposure, and 3) design and imple-
ment updated surveillance and evaluation strategies (Box).
1. Update Blood Lead Screening 
Policies for Medicaid-Eligible Children 
Since the 1997 CDC recommendation for targeted blood 
lead screening, certain jurisdictions have collected reliable 
BLL data that do not show higher rates of EBLLs among 
children enrolled in Medicaid compared with children not 
enrolled in Medicaid. Such data challenge the assumption 
that all Medicaid-eligible children are at increased risk for 
EBLLs, an assumption that forms the basis of the current 
national Medicaid policy for blood lead screening. The find-
ings underscore the need for closer analysis of the lead risk 
patterns within various jurisdictions and suggest that blood 
lead screening of children in Medicaid populations should 
be targeted toward subgroups at higher risk rather than all 
Medicaid-eligible children. 
In 1997, CDC endorsed continued universal screening 
of Medicaid children unless reliable data demonstrated “the 
absence of lead exposure in this population.” Developing 
policies consistent with this recommendation is challenging 
because of the difficulty of proving an absence of lead expo-
sure. A more effective policy would be to enable state-level 
flexibility in developing screening policies appropriate for 
local patterns of risk for lead exposure and to give states the 
option of integrating their Medicaid-eligible populations into 
other targeted lead screening plans. With this policy change, 
the decision regarding whether to screen all Medicaid-eligible 
children for lead exposure would be made at the state and local 
levels, rather than the national level. State and local public 
health authorities are more familiar than federal agencies with 
local lead-risk exposure patterns and are therefore better able 
to develop and implement screening strategies to identify spe-
cific groups of children who are at risk. Such a policy would 
decrease the number of children tested who are not at risk, 
which would reduce health-care costs and address concerns 
among health-care providers regarding unwarranted blood 
lead testing for children.
To implement this new policy, state and local public health 
authorities should review data associated with risk for lead 
exposure (e.g., age of housing, percentage of rental properties 
and young children in a community, and sources of lead in 
the environment) and from blood lead surveillance  to identify 
geographic areas where children are at risk for EBLLs. Public 
health authorities must ensure the validity and reliability of 
the data and analyses used to justify screening policy decisions 
and should seek assistance from CDC when needed.
† Social Security Act, Title 42. The public health and welfare. Chapter 7, Title 
XIX. Grants to states for medical assistance programs. 42 U.S.C. Sect 1396d 
(1999).
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In 2008, the National Committee for Quality Assurance 
(NCQA) began collecting data for a new Health-Care 
Effectiveness Data and Information Set (HEDIS) performance 
measure of blood lead testing for children enrolled in Medicaid 
managed care plans. Data from NCQA HEDIS surveys are 
used by consumers, health plan administrators, and purchas-
ers of employee-based group health insurance to compare 
the quality and effectiveness of health-care services provided 
by various managed care plans and individual health-care 
providers. HEDIS data are used as the basis for health plan 
report cards and rankings that are published in newspapers 
and magazines§; therefore, HEDIS results can be a power-
ful incentive for health-care plans to provide quality care. 
The HEDIS performance measure for lead screening among 
Medicaid-eligible children will provide baseline data that states 
can use to determine geographic areas where increased blood 
lead testing is needed, as well as areas where BLLs are low 
enough that universal testing is no longer warranted. Initial 
data from a 2005 review of six geographically diverse health 
plans with varying numbers of enrolled children indicate that 
blood lead testing rates in the plans ranged from 49% to 85% 
during the year (25). 
States with Data-Driven Lead 
Screening Recommendations for 
non–Medicaid-Eligible Children
Since the 1997 CDC recommendations were made, all 42 
CDC-funded childhood lead poisoning prevention programs 
in 37 states have developed data-driven targeted screening 
recommendations. Agencies in these states and localities have 
assessed local lead exposure risks, reviewed surveillance and 
census data, identified relevant factors of local importance, and 
developed infrastructures for involving relevant persons in the 
assessment process. In addition, state blood lead surveillance 
systems have improved through more complete collection 
and analysis of blood lead data (11), and many states have 
established community-wide lead exposure assessment and 
analysis programs. 
After the State Medicaid Manual is updated to allow targeted, 
rather than universal, blood lead testing of children enrolled 
in Medicaid, state-level lead poisoning prevention programs, 
in partnership with state Medicaid agencies and members of 
state lead advisory committees, should analyze available data on 
lead screening and exposure patterns in the Medicaid-eligible 
population and modify their lead screening recommendations 
on the basis of local factors. For example, one such analysis 
BOX. Blood lead screening of Medicaid-eligible children aged 
1–5 years: recommendations for state and local public health 
officials 
1. Update blood lead screening policies for Medicaid-
eligible children.
At the population level, evaluate risk data among •	
all children and the risk for lead exposure among 
Medicaid-eligible children.
In states with data-driven lead screening recommen-•	
dations for non–Medicaid-eligible children, health 
officials should initiate a participatory process among 
all stakeholders that involves screening Medicaid-
eligible children according to established local risk 
factors per the targeted statewide lead screening 
recommendations.
In states without data-driven lead screening recom-•	
mendations for non–Medicaid-eligible children, 
health officials should provide basic lead screening 
guidance online and through other communication 
channels that reach health-care providers.
2. Improve rates of blood lead screening for 
Medicaid-eligible children determined to be at 
increased risk for lead exposure.
Alert health-care providers to known risks for lead •	
exposure.
Link data from the blood lead surveillance system •	
and Medicaid encounter system to monitor screen-
ing performance, track blood lead levels (BLLs), and 
identify gaps in screening.
Provide incentives or penalties for health-care provid-•	
ers according to rates of blood lead screening.
Collaborate with the Special Supplemental Nutrition •	
Program for Women, Infants, and Children (WIC) 
to encourage blood lead testing at WIC sites. 
Consider alternative screening technologies as part •	
of a strategy to increase testing of children at high 
risk for lead exposure. 
3. Design and implement updated surveillance and 
evaluation strategies.
Design and implement surveillance systems not only •	
for BLLs but also for environmental lead levels.
Evaluate blood lead screening policies by using the •	
Health-Care Effectiveness Data and Information Set 
(HEDIS) and other performance measures.
involved a study of physician screening practices in Michigan 
to determine risk factors associated with rates of blood lead 
testing and the proportion of children with EBLLs among 
Medicaid-enrolled children. Results indicated that specific 
§ Information on HEDIS and measurement of health-care quality available at 
http://www.ncqa.org/tabid/59/default.aspx.
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risk factors for lead exposure were associated with higher rates 
of lead screening and increased BLLs within subgroups of 
children, suggesting that assessments in pediatric health-care 
settings can be used to identify subpopulations of Medicaid-
enrolled children who are at risk for EBLLs (26). In addition 
to considering unique local lead hazard data, states should 
examine whether specific targeted screening strategies should 
be incorporated for children in populations who have been 
identified as being at risk for EBLLs, such as recent immigrants, 
refugees, or foreign adoptees (27–29). 
Until state-level lead screening recommendations are 
revised to include targeted strategies for subpopulations of the 
Medicaid-eligible population, states that already have recom-
mendations in place for targeted screening of children who are 
not eligible for Medicaid should decide whether to continue to 
require testing of all Medicaid-eligible children (i.e., continue 
to assume that all these children are at increased risk) or to 
immediately subsume Medicaid-eligible children under the 
existing targeted screening strategy for the non–Medicaid-
eligible population (i.e., assume that Medicaid-eligible children 
have the same risk as non–Medicaid-eligible children within 
the state). For example, an interim state plan for a state that 
decides to screen Medicaid-eligible children using the exist-
ing strategy for the non–Medicaid-eligible population might 
include testing all Medicaid-eligible children who live in zip 
codes with high proportions of persons at high risk for EBLLs, 
as well as testing children who meet the screening criteria for 
Medicaid-eligible children. 
States Without Data-Driven Lead Screening 
Recommendations for non–Medicaid-Eligible 
Children 
States that do not have lead screening recommendations 
in place or that have no CDC funding for such plans should 
analyze community-level data on risk for lead exposure, 
including the age and condition of local housing (30,31). 
At the local level, information regarding housing condition 
might be available from tax assessors or local code enforcement 
agencies. If the information is unavailable, the percentage of 
rental or abandoned properties in a neighborhood is a useful 
proxy for housing condition (32). In addition, over time, local 
data on age of housing changes as housing ages or is abated, 
renovated, demolished, or replaced with new construction (4). 
Periodically, or on an ongoing basis, these states should also 
conduct comprehensive reviews of potential local environ-
mental lead sources to ensure that prevention policies reflect 
local risk. Industrial and government data on lead releases or 
environmental lead measurements are available from various 
sources, such as the EPA’s National Ambient Air Quality pro-
gram, Toxic Release Inventory, and Superfund program.¶ 
The nine states without lead screening plans should continue 
to perform universal blood lead screening of Medicaid-enrolled 
children until these states have completed assessments of risk 
for lead exposure among these children, reached consensus 
on data-driven primary and secondary lead poisoning preven-
tion strategic plans for the community (including blood lead 
screening), and implemented these plans. The 1997 CDC lead 
screening recommendations include guidance on involving 
community stakeholders in such a process (21).
Blood Lead Screening Criteria for Medicaid-
Eligible Children
The following screening criteria should be incorporated 
in all state plans (21). A Medicaid-eligible child who meets 
any one of the following criteria should receive a blood lead 
screening test: 
Child is suspected by a parent or a health-care provider to •	
be at risk for lead exposure. 
Child has a sibling or frequent playmate with EBLL.•	
Child is a recent immigrant, refugee, or foreign adoptee •	
(27–29).
Child’s parent or principal caregiver works professionally •	
or recreationally with lead (22,33).
Child has a household member who uses traditional, •	
folk, or ethnic remedies or cosmetics or who routinely 
eats food imported informally (e.g., by a family member) 
from abroad (22). 
Child’s family has been designated at increased risk for lead •	
exposure by the health department because the family has 
local risk factors for lead exposure (e.g., residence in a des-
ignated high-risk zip code or near a known point source).
2. Improve Rates of Blood Lead 
Screening Among Medicaid-Eligible 
Children Determined To Be at 
Increased Risk for Lead Exposure
State and federal Medicaid agencies and their partners 
should work to improve screening rates of Medicaid-eligible 
children at risk for lead exposure. Although children who are 
eligible for Medicaid can no longer be assumed to have an 
increased risk for EBLLs, certain Medicaid-eligible children 
will still need blood lead screening and would benefit from 
follow-up services. Results from the 1999–2004 NHANES 
survey indicate that 41.9% of Medicaid-enrolled children aged 
¶ Data regarding lead in consumer products is available from CDC at http://
www.cdc.gov/ncheh or from the Consumer Product Safety Commission at 
http://www.cpsc.gov.
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1–5 years had received at least one blood lead test before their 
NHANES examination (1). Data from other studies indicate 
a broader range of compliance with routine Medicaid screen-
ing policies (10,34–36). In the years since Medicaid-eligible 
children were identified as a group at high risk for EBLLs, 
numerous strategies to improve blood lead screening rates for 
this population have been suggested (16,37). Many of these 
strategies have been implemented, and some have been evalu-
ated for effectiveness (38–40). 
Establish Screening Policies that Reflect Local 
Risk for Lead Exposure
State-issued lead screening recommendations might be more 
likely to be followed than the current national Medicaid policy 
and might increase blood lead screening rates. Health-care 
providers might be more likely to follow screening recom-
mendations that they believe more accurately reflect local risk 
for lead exposure and that they helped develop. In addition, 
state and local health authorities are likely to be more famil-
iar with local conditions and therefore in a better position 
than national authorities to monitor and improve screening 
performance for Medicaid-eligible children at high risk for 
EBLLs. In most CDC-funded, state-level lead poisoning pre-
vention programs, state lead surveillance data and Medicaid 
enrollment records of children can be matched electronically 
to assess rates of lead screening and examine BLLs in this 
group (41). State and local health authorities should consider 
practicality when developing screening recommendations for 
Medicaid populations and ensure that recommendations are 
feasible and realistic. Many screening policies that could be 
adopted at the state or local level might not require health-care 
providers to assess individual patient risk before testing. States 
could decide to 1) screen all Medicaid-eligible children, 2) 
use the same screening policies for Medicaid-eligible children 
and children in the general population, or 3) use objective 
criteria to determine which populations should be screened 
(e.g., residence in a certain zip code, membership in a certain 
health maintenance organization, or immigration status). 
The effectiveness of personal risk assessment questionnaires 
administered to persons in the offices of health-care providers 
is often limited, and such questionnaires might be impractical 
in certain practice settings (42–44). 
Provide Scientific Risk Information to Health-
Care Providers
In 2000, CDC recommended that scientific information 
be provided to health-care providers regarding Medicaid 
blood lead screening policies and related data, assuming that 
health-care providers are more likely to implement clinical 
practice guidelines if they know that the guidelines are based 
on scientific evidence. In addition, evidence suggests that 
lead screening practices are influenced by physician percep-
tions of the level of importance of lead poisoning prevention 
(45). Studies of lead screening behaviors of physicians have 
supported these assumptions and findings (45,46). Successful 
risk communication models also have been described, such as 
the development of locally customized maps of lead hazard 
data created by the Wisconsin Childhood Lead Poisoning 
Prevention Program, using Geographic Information Systems 
(GIS) software to plot data on EBLLs and housing age (47). 
For example, GIS can be used to generate maps that identify 
where children at high risk for EBLLs live by showing BLLs 
of resident children for a given time period, as well as the age 
and location of each housing unit in an area. These GIS maps 
can be used to clarify changes in neighborhood risk status over 
time and evaluate the impact of lead screening strategies on 
local BLLs. CDC has developed guidance for the use of GIS 
in lead poisoning prevention (48). 
Link and Share Data Between Medicaid and 
State Lead Surveillance Systems
Since 1998, CDC has been encouraging states to link their 
blood lead surveillance databases with their databases for 
Medicaid encounters by requiring CDC-funded childhood 
lead poisoning prevention programs to have a system for 
ongoing identification of Medicaid-eligible children in the 
surveillance system.** Successfully linking these databases 
can improve screening of children at high risk for EBLLs by 
identifying gaps in service delivery (e.g., by generating lists 
of unscreened Medicaid-enrolled children by their name and 
the name of their health-care provider) and improve the accu-
racy of surveillance and Medicaid reports (e.g., by including 
Medicaid status with test results in the surveillance system). 
When data systems are linked and the records have informa-
tion about characteristics such as Medicaid status, health plan 
enrollment, race/ethnicity, and address, more focused analyses 
can be conducted (e.g., determining screening rates by zip 
code or by managed care plan). The information also can be 
provided to health-care providers, managed care organizations, 
and others who can use the information to improve service 
delivery. Although states have begun linking data and can 
track screening tests for Medicaid enrollees, almost none of 
the programs have reported on their use of these systems to 
track and analyze rates of EBLLs among the Medicaid-enrolled 
children who are tested. 
 ** Grants to states for medical assistance programs: definitions. 42 U.S.C. Sect. 
1396d (1999).
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Motivate Health-Care Providers 
Strategies to motivate health-care providers to provide lead 
screening to Medicaid-eligible children, such as measuring 
performance and providing feedback or providing financial 
incentives or penalties, are being used in many areas. Studies 
have shown that measuring performance and providing feed-
back on the delivery of health-care services affect the practices 
of health-care providers and health-care plans, including 
increasing screening rates (49,50). Linked databases have 
previously been used to analyze screening rates or EBLL rates 
among patients of individual health plans or physicians and 
to provide feedback to health-care providers on their screening 
performance. Certain jurisdictions (e.g., New York and Rhode 
Island) or Medicaid managed care plans provide individual 
health-care plans and physicians with names of children 
who need screening (51,52). The state of Wisconsin prepares 
customized report cards that provide data on lead screening 
performance and risk for lead exposure to health-care provid-
ers. In addition, a performance measure for lead screening of 
Medicaid-enrolled children was added to HEDIS in 2008 (53). 
Finally, task-specific financial incentives or penalties are being 
used in several states (e.g., Maine, Minnesota, New York, and 
Wisconsin) to increase performance of lead screening, such 
as state contracts offering incentives or penalties to managed 
care plans and health plans offering incentives or penalties to 
participating health-care providers (45,54,55). 
Establish Partnerships with WIC 
A strategy that was previously recommended by CDC is 
increasingly being used to provide blood lead testing services 
to children who are in low-income families and at high risk for 
EBLLs. WIC enrollment, which is a useful proxy for Medicaid 
enrollment, is used to increase screening rates among Medicaid-
eligible children (56,57). A new law in Michigan requires that 
all children whose families receive WIC benefits be given lead 
screening tests.†† CDC has provided technical assistance to 
states in testing, designing, and evaluating such collabora-
tive strategies. Several successful measures have recently been 
reported in the state Medicaid directors’ newsletter (57). The 
primary challenge with the WIC enrollment strategy is that 
WIC and health agencies must work together to reimburse 
WIC clinics that test Medicaid-eligible children for lead 
poisoning. The city of Chicago, Illinois; the city of Newark, 
New Jersey; and the states of Ohio and Wisconsin have all 
collaborated with WIC to increase Medicaid screening rates 
for target populations (57). Collaboration with WIC also has 
been used as an effective blood lead screening strategy among 
Native American children (58). 
Use Alternative Screening Technologies 
Research indicates that performing blood lead screening in 
physicians’ offices reduces barriers to screening (45), both for 
parents, who have reported that testing in a physician’s office 
is preferable to traveling elsewhere (59), and for physicians, 
who do not have to send samples to outside laboratories to 
obtain results. To make the process of lead screening easier and 
more accessible for families, programs have experimented with 
testing alternatives, such as providing screening at WIC sites 
and using blood lead testing instruments in clinical offices 
(60,61). Since 1997, a portable device approved by the Food 
and Drug Administration (FDA) for blood lead analysis has 
been available that provides instant blood lead screening results, 
enabling rapid follow-up care and immediate collection of a 
venous blood sample to confirm an EBLL result from a capil-
lary sample. The most recent version of this portable device 
does not require specific laboratory certifications. Even with 
the previous device, which required certification, certain states 
(e.g., Washington) increased lead screening rates (61). Another 
method of on-site sample collection involves using filter paper 
to store and transmit blood samples for analysis. CDC has 
encouraged study of the use of filter paper, which is being 
used in several states routinely (e.g., Kansas, Minnesota, and 
Wisconsin) or for special projects (e.g., New Jersey). Both the 
portable device and filter paper can be used with capillary or 
venous blood samples. Concerns about sample contamination 
are associated with failure to adequately clean the skin site, 
not the device that transports or analyzes the sample. In areas 
where the benefits (e.g., increased screening rates) of capillary 
sample collections outweigh the drawbacks, CDC encourages 
use of capillary sampling, following recommended proto-
cols, to encourage increased screening (62). CDC provides 
technical support and training for proper capillary sampling, 
including a DVD on proper sample technique.§§ Elevated 
capillary BLLs should be confirmed through venous blood 
testing and sound analytic methods, such as graphite furnace 
atomic absorption.
3. Design and Implement Updated 
Surveillance and Evaluation 
Strategies
Use Surveillance Strategies to Track Blood 
Lead Levels
NHANES remains an effective tool for generating national 
estimates of children aged 1–5 years with EBLLs and evalu-
ating nationwide primary prevention interventions. CDC 
also has begun working with states to develop alternative 
 †† Michigan Public Act 286 of 2006. Sect. 111l, 93rd Legis., Reg. Sess. (2006).  §§ Sampling information available at http://www.cdc.gov/nceh/lead.
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surveillance strategies to detect increases in the proportion of 
populations with EBLLs and to identify new lead sources in 
communities.
After the State Medicaid Manual is updated, states that 
discontinue universal lead screening of Medicaid-eligible 
children because these children have been determined to be at 
low risk for lead exposure should conduct active surveillance 
of known groups and geographic areas at high risk for EBLLs 
to monitor trends and confirm that risk remains low. In such 
areas, state health departments and Medicaid programs are 
encouraged to monitor lead exposure risk by reviewing BLL 
laboratory data, alerting the public about newly identified 
sources of lead exposure, and initiating focused BLL prevalence 
surveys. For example, local prevalence studies can be designed 
to be representative of the area studied. One CDC-supported 
study in Chicago, prompted by a request from local health 
officials, found that in one community, approximately 30% 
of children aged 1–5 years had EBLLs (63). Children who are 
recent immigrants, refugees, or foreign adoptees also should 
be monitored for EBLLs (27–29). These types of assessments 
help ensure that existing screening policies are adequate and 
appropriate and can provide an early warning of an increase in 
or reemergence of EBLLs in a particular community. 
Another important component of EBLL surveillance is 
identifying other subpopulations of Medicaid-eligible chil-
dren who are at increased risk for EBLLs (e.g., children of 
parents who work with lead or children who live close to a lead 
smelter or mine) but are not receiving needed lead screening. 
Identification of these children should be based primarily on 
data that indicate whether children who were thought to be 
at low risk for EBLLs remain at low risk. Sources of such data 
might include census data, nutritional evaluations (e.g., WIC 
records), housing surveys, adult and occupational lead registry 
data, and identification of new products or practices resulting 
in lead exposure within the community. New or increased risk 
for EBLLs identified in a subpopulation might prompt updated 
screening recommendations.
An EBLL surveillance system should include routine collec-
tion of data on well-defined populations and environmental 
indicators. For example, data might routinely be collected on 
the number of prescriptions filled for lead-chelating agents in 
a sample of cities so that a substantial increase in prescriptions 
could be identified. Because EBLLs have an environmental 
origin, environmental indicators (e.g., lead dust in housing 
that receives federal subsidies) also should be included. An 
EBLL surveillance system should help states identify previously 
unrecognized lead exposures, especially in states without lead 
screening plans; CDC and its federal and state partners are 
well positioned to identify a core set of measures for an EBLL 
surveillance system. 
Evaluate CDC and CMS Blood Lead Screening 
Policies
To make appropriate policy modifications after the State 
Medicaid Manual is updated and provide useful technical assis-
tance to state partners, CDC and CMS will evaluate regularly 
the effectiveness of federal lead screening and treatment policies 
to determine whether children who would benefit from blood 
lead screening are being tested and, if they are not, will take 
steps to ensure this goal is accomplished. Simultaneously, CDC 
and CMS will develop an evaluation framework to measure 
the results of the changed screening policies and programs. In 
accordance with CDC’s Framework for Program Evaluation in 
Public Health (64), the evaluation will include the following: 
Number and proportion of children targeted for screening •	
who received screening
Number and proportion of tested children who are identi-•	
fied as having EBLLs
Number and proportion of children with EBLLs who •	
received complete environmental investigations, for whom 
lead hazards were identified, and for whom lead hazards 
were remediated
Information about follow-up services provided, including •	
the number of children with EBLLs who received case 
management services
Data system measures and goals•	
CDC and CMS will use numerous data sources to evaluate 
federal blood lead screening policies, including CDC-funded 
and non–CDC-funded state surveillance systems and pro-
gram documentation, state Medicaid agencies (e.g., data from 
the CMS EPSDT report [form 416] on the number of lead 
screening tests reported for Medicaid enrollees), GIS analysis 
of environmental and health data, focused survey results, 
private-sector data collection instruments (e.g., Medicaid 
HEDIS), and other federal agencies (the Consumer Product 
Safety Commission, FDA, EPA, or HUD). 
Conclusion
BLLs decreased in the United States population overall and 
in every subpopulation during 1976–2004. BLLs decreased 
among certain Medicaid-enrolled children, but the geographic 
disparities increased. These findings suggest that a national 
blood lead screening policy that requires universal screening 
of all young Medicaid-eligible children is not justified. State 
and local public health authorities are better positioned, with 
assistance from CDC, to assess local risk variations, develop 
appropriate screening policies to identify EBLLs among 
Medicaid-eligible children, and develop and evaluate lead 
screening strategies. To help ensure that Medicaid-eligible 
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children who are at risk for lead poisoning are identified and 
treated appropriately, 1) decisions regarding the level of risk 
for EBLLs among Medicaid-eligible children should be made 
by state and local health departments; 2) lead screening tests 
should be provided at WIC sites, and new blood lead testing 
technologies should be considered; and 3) existing surveillance 
systems should be refined to include other measures of risk of 
exposure, including environmental measures, so that they are 
not solely dependent on BLL testing for identifying risk for 
lead poisoning. 
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